Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACT001 and Pembrolizumab in Recurrent Glioblastoma Multiforme
NCT05053880Phase 2Active, not recruiting
- Sponsor
- Accendatech
- Start
- Sep 2021
- Primary completion
- Oct 2024
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dimethylaminomicheliolide in glioblastoma multiforme (GBM), sponsored by Accendatech. Started Sep 2021; status: active, not recruiting.
02
Drugs
dimethylaminomicheliolide
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT05053880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05053880.